Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
bởiAudrey Abella
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
03 Aug 2023

Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?
31 Jul 2023
In patients with neovascular age-related macular degeneration (nAMD) who switched to brolucizumab treatment, those with shorter treatment interval before switching are more likely to have successful injection interval extension, as shown in a study.
31 Jul 2023






